Amgen's dividend looks great, and the stock is reasonably valued. Even so, there remain strong reasons to invest in Amgen and ...

Amgen (AMGN) is eyeing the obesity drug race, currently dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), with its two late-stage weight-loss drug trials. Citi Research managing director Geoff ...

First there were Victoza and Saxenda, then Ozempic seized the spotlight - followed by Wegovy and Mounjaro. And ever-better ...

Dr. Osama Hamdy, the acclaimed Egyptian physician at Harvard who consistently educates the public on medical breakthroughs, ...

A weekly selection of opinions and analyses from the Arab media around the world. From Gaza Tunnels to New York ...

Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside ...

Viking Therapeutics VKTX remains one of the few clinical-stage biotechs making meaningful progress in obesity drug ...

The Fund lost value but held up significantly better than the Index during the quarter. Stock selection within biotechnology, pharmaceuticals, and life sciences tools & services, along with an ...

The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg ...

Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity ...

As semaglutide hits pharmacy shelves for $499, doctors weigh the pros and cons of brand-name vs. compounded meds.

GLP-1 injections use needles and require refrigeration. Pills that work in a similar way could be a cheaper, simpler solution.